H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals

Article

H.I.G. Capital’s portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals.

H.I.G. Capital, a global alternative investment firm, announced on Oct. 3, 2022 that its portfolio company Aspire Pharma has acquired Morningside Healthcare and Morningside Pharmaceuticals, a UK provider of niche generic and branded specialty pharmaceuticals. The financial terms of the transaction have not been disclosed.

Morningside is focused on developing and licensing niche generic pharmaceutical products, marketing over 160 stock keeping units across more than 80 product families and multiple therapeutic areas. According to a company press release, H.I.G. is combining Morningside with Aspire Pharma to build growth, product development, and support new initiatives, such as international expansion.

“We are excited to welcome the Morningside team to the Aspire family,” said Richard Condon, CEO of Aspire, in the release. “This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally.”

Source: H.I.G. Capital

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content